Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reactivation Clear all
Recruiting Not applicable Interventional

Micromanaging Human Sleep Physiology to Treat Sleep Apnea and Other Disorders

NCT06926036
View directory record Official record
Conditions
Sleep Apnea Obstructive (OSA)
Interventions
Wake training + TMR
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

NCT05595369
View directory record Official record
Conditions
Long COVID, Long Covid19
Interventions
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 21, 2026, 10:48 PM EDT
Terminated Phase 3 Interventional Results available

Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

NCT04706507
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
IV Ganciclovir, Normal saline
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy

NCT04663672
View directory record Official record
Conditions
Claustrophobia, Obsessive-Compulsive Disorder, Arachnophobia
Interventions
Experimental Scent, Control Scent, No-Scent Control, In-Vivo Exposure
Other · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Daratumumab in STK11 Mutated NSCLC

NCT05807048
View directory record Official record
Conditions
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
Interventions
Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication, Post-Intervention Medication
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Terminated Not applicable Interventional Results available

Continuous Labor Epidural Catheter for Tubal Ligation Study

NCT00898443
View directory record Official record
Conditions
Tubal Ligation, Bilateral Tubal Ligation
Interventions
Epidural anesthetic, Spinal anesthetic
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Direct Context Reactivation During Sleep on Memory

NCT04702152
View directory record Official record
Conditions
Sleep, Consolidation
Interventions
Targeted memory reactivation (sounds)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 21, 2026, 10:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Donor-Derived Viral Specific T-cells (VSTs)

NCT02048332
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Interventions
Viral specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Weeks and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
3
States / cities
Akron, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
No Longer Available No phase listed Expanded access

Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)

NCT01945619
View directory record Official record
Conditions
EBV Infection, CMV Infection, Adenoviral Infection
Interventions
Trivirus-Specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 21, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

Combining MyoCI With Memory Reactivation to Improve Motor Recovery After Stroke

NCT04312269
View directory record Official record
Conditions
Stroke
Interventions
Targeted Memory Reactivation (TMR)
Other
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

NCT00723229
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 21, 2026, 10:48 PM EDT
Not yet recruiting Phase 1 Interventional

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07737769
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection, Bone Marrow Biopsy, Busulfan, Fludarabine
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Terminated Phase 3 Interventional Results available

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

NCT03887702
View directory record Official record
Conditions
Hepatitis B Infection, Malignant Solid Neoplasm
Interventions
Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
Other · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
192
States / cities
Fort Smith, Arkansas • Anaheim, California • Antioch, California + 140 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

NCT01063829
View directory record Official record
Conditions
HCMV Reactivation or HCMV End-Organ Disease
Interventions
60 mg AIC246, 120 mg AIC246, 240 mg AIC246, Placebo
Drug · Other
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

NCT00711035
View directory record Official record
Conditions
Adenovirus Infection, EBV Infection
Interventions
Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 21, 2026, 10:48 PM EDT
Completed No phase listed Observational

Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010

NCT03111745
View directory record Official record
Conditions
Viral Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 85 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Completed No phase listed Observational

JC Virus Reactivation in Multiple Sclerosis

NCT02004444
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 21, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

NCT02727998
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

NCT00530218
View directory record Official record
Conditions
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Leukemia, Lymphoma, Multiple Myeloma, MDS, Myelodysplastic/Myeloproliferative Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders

NCT01631682
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Anxiety Disorder
Interventions
Propranolol, Reactivation, Mifepristone, Intranasal oxytocin
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 10:48 PM EDT
Completed No phase listed Observational

Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection

NCT03248622
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

NCT03382834
View directory record Official record
Conditions
HIV Infections
Interventions
Tamoxifen, Vorinostat, Antiretroviral drugs
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 10:48 PM EDT
Completed No phase listed Observational

Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

NCT03092505
View directory record Official record
Conditions
Herpes Virus-Related Illnesses
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 10:48 PM EDT